Trastuzumab containing regimens for early breast cancer.

ABSTRACT:

Background

Approximately one-fifth of women who develop early breast cancer have HER2-positive tumours, which if untreated, have a worse prognosis than HER2-negative tumours. Trastuzumab is a selective treatment targeting the HER2 pathway. Although the results on efficacy seem to support its use, there are potential cardiac toxicities which need to be considered, especially for women at lower risk of recurrence, or those at increased cardiovascular risk.

Objectives

To assess the evidence on the efficacy and safety of therapy with trastuzumab, overall and in relation to its duration, concurrent or sequential administration with the standard chemotherapy regimen in patients with HER2-positive early breast cancer.

Search methods

We searched the Cochrane Breast Cancer Gro

SUBMITTER: Moja L 

PROVIDER: S-EPMC6718210 | biostudies-literature | 2012 Apr

REPOSITORIES: biostudies-literature